Revitalizing Cytokine-Based Cancer Immunotherapy through Advanced Delivery Systems

Area of Science:

• Immunology
• Biotechnology
• Cancer Therapeutics

Background:

• Cytokines are crucial for immune responses and show therapeutic potential for infections, autoimmune diseases, and cancers.
• Pro-inflammatory cytokines demonstrate preclinical efficacy in cancer treatment but face clinical hurdles.
• Current approved cytokine therapies (IFN-α, IL-2) are limited, necessitating further investigation.

Purpose of the Study:

• To review innovative delivery strategies for cytokines as cancer immunotherapeutics.
• To summarize key gene and protein delivery approaches for cytokines.
• To critically examine the potential and challenges of these strategies for clinical translation.

Main Methods:

• Review of existing literature on cytokine delivery systems for cancer therapy.
• Analysis of gene delivery methods (DNA, mRNA) targeting cytokines to tumors.
• Examination of protein delivery strategies for enhanced cytokine therapy.

Main Results:

• Delivery systems offer a promising avenue to overcome pharmacokinetic and toxicity limitations of cytokine therapy.
• Targeted delivery of cytokines or their encoding nucleic acids to tumor tissues can enhance anticancer efficacy.
• Both gene and protein delivery strategies present unique advantages and challenges for clinical application.

Conclusions:

• Innovative delivery systems are essential to improve the safety and anticancer performance of cytokine therapeutics.
• Targeted delivery approaches hold significant potential for advancing cytokine-based cancer immunotherapy.
• Further research and development are needed to overcome challenges and facilitate clinical translation of these advanced therapies.